[Hisco: Innovative drug HSK42360-Na tablets are included in the Breakthrough Therapy Drug Program] On September 27, Hisco (002653.SZ) announced that the company's innovative drug HSK42360-Na tablets were officially included in the "Breakthrough Therapy List" by the Drug Evaluation Center of the State Food and Drug Administration for the treatment of recurrent or progressive high-grade gliomas with BRAFV600 mutations. The drug is a BRAF paradoxicalbreaker inhibitor independently developed by the company. It has excellent central nervous system penetration. Clinical trials that have been carried out have shown outstanding efficacy and controllable safety. After being included as a breakthrough therapy, it is expected to obtain priority review qualifications during the marketing application stage and accelerate the marketing process.